Literature DB >> 27493150

Accessory renal arteries: Prevalence in resistant hypertension and an important role in nonresponse to radiofrequency renal denervation.

Paige VonAchen1, Jason Hamann2, Thomas Houghland1, John R Lesser1, Yale Wang1, David Caye1, Kristi Rosenthal1, Ross F Garberich1, Mary Daniels3, Robert S Schwartz4.   

Abstract

OBJECTIVE: The aim of this study was to understand the role of accessory renal arteries in resistant hypertension, and to establish their role in nonresponse to radiofrequency renal denervation (RDN) procedures.
BACKGROUND: Prior studies suggest a role for accessory renal arteries in hypertensive syndromes, and recent clinical trials of renal denervation report that these anomalies are highly prevalent in resistant hypertension. This study evaluated the relationships among resistant hypertension, accessory renal arteries, and the response to radiofrequency (RF) renal denervation.
METHODS: Computed Tomography Angiography (CTA) and magnetic resonance imaging (MRI) scans from 58 patients with resistant hypertension undergoing RF renal denervation (RDN) were evaluated. Results were compared with CT scans in 57 healthy, normotensive subjects undergoing screening as possible renal transplant donors. All scans were carefully studied for accessory renal arteries, and were correlated with long term blood pressure reduction.
RESULTS: Accessory renal arteries were markedly more prevalent in the hypertensive patients than normotensive renal donors (59% vs 32% respectively, p=0.004). RDN had an overall nonresponse rate of 29% (response rate 71%). Patients without accessory vessels had a borderline higher response rate to RDN than those with at least one accessory vessel (83% vs 62% respectively, p=0.076) and a higher RDN response than patients with untreated accessory arteries (83% vs 55%; p=0.040). For accessory renal arteries and nonresponse, the sensitivity was 76%, specificity 49%, with positive and negative predictive values 38% and 83% respectively.
CONCLUSIONS: Accessory renal arteries were markedly over-represented in resistant hypertensives compared with healthy controls. While not all patients with accessory arteries were nonresponders, nonresponse was related to both the presence and non-treatment of accessory arteries. Addressing accessory renal arteries in future clinical trials may improve RDN therapeutic efficacy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypertension; Renal denervation

Mesh:

Substances:

Year:  2016        PMID: 27493150     DOI: 10.1016/j.carrev.2016.07.009

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  5 in total

Review 1.  Patient Selection for Renal Denervation in Hypertensive Patients: What Makes a Good Candidate?

Authors:  Sheran Li; Jacqueline K Phillips
Journal:  Vasc Health Risk Manag       Date:  2022-05-13

2.  Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension.

Authors:  Lucas Lauder; Sebastian Ewen; Abraham Rami Tzafriri; Elazer Reuven Edelman; Thomas Felix Lüscher; Peter J Blankenstijn; Oliver Dörr; Markus Schlaich; Faisal Sharif; Michiel Voskuil; Thomas Zeller; Christian Ukena; Bruno Scheller; Michael Böhm; Felix Mahfoud
Journal:  EuroIntervention       Date:  2018-05-20       Impact factor: 6.534

3.  Renin dependent hypertension caused by accessory renal arteries.

Authors:  Pei Lin Chan; Florence Hui Sieng Tan
Journal:  Clin Hypertens       Date:  2018-11-01

4.  Relationship between Accessory Renal Artery and Clinical Characteristics of Middle-Aged Patients with Primary Hypertension.

Authors:  Kai Kang; Yeshuo Ma; Chongfu Jia; Yunpeng Cheng; Yingchao Yang; Lixin Wang; Yinong Jiang; Yan Lu
Journal:  Int J Hypertens       Date:  2020-04-08       Impact factor: 2.420

5.  Correlation between Renal Artery Anatomy and Hypertension: A Retrospective Analysis of 3000 Patients.

Authors:  Jiayi Shen; Lingchun Lyu; Xiaoyan Wu; Jiansong Ji; Chunlai Zeng; Shan Li; Yanan Zhao; Jian Xu; Li Lin; Chenyin Lu; Wei Mao; Tiemin Wei
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-29       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.